Vector

Vector BioMed has developed a technology platform for designing and manufacturing the lentiviruses used to deliver cell and gene therapies.

Vector BioMed is entering the mix with a technology platform that it says provides algorithm-optimized lentiviral vectors with superior function and vector titers, the number of vector particles that can deliver the therapeutic payload by infecting a cell. Rubins, Ivanishin, and Onishi will spend approximately four months on the orbital complex, returning to Earth in October. “Now is the perfect time to launch our business,” Dropulić said in a prepared statement. Vector BioMed was co-founded by Boro Dropulić, who has been named CEO in conjunction with the financing and company launch. Vector BioMed, a new CDMO with a focus on producing lentiviral vectors, is stepping up to fill the void. Most cell and gene therapy developers turn to a contract manufacturer for viral vectors rather than make them internally.

The manufacture of lentiviral vectors has been grabbing the attention of investors both small and large as of late, and another manufacturer is looking to ...

[raised](https://www.prnewswire.com/news-releases/biomanufacturing-company-vector-biomed-launches-with-mission-to-provide-access-to-high-quality-lentiviral-vectors-and-address-the-vector-supply-bottleneck-301733937.html) $15 million, according to CEO Boro Dropulić in an interview with Endpoints News. The impetus behind the company, Dropulić said, is for Vector BioMed to fill a gap in the demand and access to lentiviral vectors, a key component in CAR-T therapies and other treatments. Vector BioMed launches with $15M to produce backlogged CAR-T component

PRNewswire/ -- Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first ...

Dropulić for decades, and his reputation in the lentiviral vector space is well-known, having led the first-ever clinical trial that established the safety of lentiviral vectors in humans. They bring significant resources and expertise to accelerate our goal to become the preferred solution for partners needing Lentiviral vectors for clinical development and commercialization of their therapeutic candidates." He and his team also developed the original lentiviral vector that is used in the production of Kymriah®, the first FDA-approved gene therapy product. Vector BioMed is the first company to be originated by Vector Biomed Co-Founder and board member James Kenny added: "Vector BioMed's management team has decades of experience in the commercialization of lentiviral vector technologies. "With the FDA granting approval of several gene therapy products, there is now a tremendous demand for the manufacture of lentiviral vectors, which are critical for clinical trials and commercialization. Dropulić added: "We are delighted to be partnered with Viking and Casdin, both highly experienced investors in the cell and gene therapy space. Vector BioMed aims to transform the industry by providing algorithm-optimized, high-titer, and high-quality Lentiviral vectors for partners that seek to move quickly to clinical trials and commercialization. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization. Vector BioMed will help address the industry's current vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, GMP manufacturing, and other support services. There is currently an 18–24-month backlog for lentiviral vector manufacturing services. 31, 2023 /PRNewswire/ -- Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital.

Led by a local industry veteran, the startup aims to fill a "significant market need."

He declined to disclose revenue targets, but said as a public benefit corporation that partners with Caring Cross, Vector Biomed devotes 10% of its capacity to produce vectors for companies serving patients in developing countries. Vector BioMed took over the space in December. When that transaction closed, Dropulić became chief science officer and general manager of Lentigen, which became a subsidiary of Miltenyi. Armed with that capital infusion, Vector BioMed is now working to stand up its operations, so it can start manufacturing vectors for the drugmakers. The firm, called Vector BioMed Inc., raised $15 million in late 2022 and is now putting that money to work — to speed up its commercial operations and bring customers on board. [approved](https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states) by the Food and Drug Administration.

By Kyle Morris Vector Capital PLC said Tuesday that it booked strong performance in 2022, with revenue growth of 12%. The U.K. lending group said in an...

Write to Kyle Morris at [email protected] The U.K. By Kyle Morris

With $15 million in funding, Vector BioMed aims to address a growing backlog for lentiviruses, a delivery tool critical for genetic medicines.

He added that his company is ready to start designing vectors and could begin manufacturing in the next couple of months. The company has its own manufacturing capabilities that it claims to be scalable, as well as vectors it’s making in-house and can offer to partners. These therapies are created from patient or donor cells genetically modified outside of the body and then infused back into the patient. New companies can have one- to two-year waits for manufacturers to make the vectors they need to advance their work. [Thermo Fisher](https://www.biopharmadive.com/news/thermo-fisher-gene-therapy-viral-vector-plant/577872/) and [Lonza ](https://www.biopharmadive.com/news/lonza-gene-therapy-texas-plant-opening/521230/)have invested heavily in viral vector manufacturing, they too are feeling the crunch. Multiple gene therapies are now approved in the U.S.